DOW JONES23,015.56+361.70 1.60%
S&P 5002,701.98+42.57 1.60%
NASDAQ8,035.89+148.63 1.88%

Barclays Initiates Coverage On Nektar Therapeutics with Overweight Rating, Announces $30 Price Target

Barclays analyst Peter Lawson initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Overweight rating and a $30 price target.

Benzinga · 03/04/2020 10:36

Barclays analyst Peter Lawson initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Overweight rating and a $30 price target.